An Gaobo: Artificial intelligence is expected to widely reshape medicine, Merck is full of confidence in the power of artificial intelligence|BEYOND Expo 2022

Technological innovation and social impact have always been the focus of BEYOND Expo. From 8:45 am to 10:00 am on September 21st, the opening ceremony of the 2nd BEYOND International Technology Innovation Expo (hereinafter referred to as “BEYOND Expo 2022”) was held in BEYOND Metaverse.

Around the theme of the opening ceremony of BEYOND Expo2022 – “What’s Next?”, the organizing committee invited Dr. Roger Kornberg, the 2006 Nobel Laureate, Chairman of the World Association of Top Scientists, and Founder of Sino-Israeli Hyde; Zheng Xuexuan, Chairman and Party Secretary of China State Construction Engineering Corporation; Shi Yigong, President of West Lake University, Academician of the Chinese Academy of Sciences; Founder of CATL , Chairman and CEO Zeng Yuqun; Hillhouse founder Zhang Lei; Merck China President, Merck Electronic Technology Executive Vice President An Gaobo; Dripguantong Group Founder and Chairman Li XiaojiaGathered in the BEYOND Metaverse, shared insights on hot topics such as the latest trends in the industry, cutting-edge technological innovation concepts, and the impact of technology in the world of future living, and talked about the future of global technological innovation.

In the keynote speech at the opening ceremony, An Gaobo, President of Merck China and Executive Vice President of Merck Electronic Technology, shared some views in the field of artificial intelligence and biomedicine, and briefly introduced Merck China’s efforts to empower medicine and health with artificial intelligence some achievements.

First of all, Angauber said that for Merck, artificial intelligence is a very important technology. He pointed out that this technology is applied in Merck’s daily business operations and R&D fields, because Merck’s broad product lines in the three major business areas of medicine and health, life sciences and electronic technology and the synergistic growth brought by artificial intelligence Effectiveness and benefits complement each other. Merck’s persistent exploration of natural science has also become more effective with the blessing of artificial intelligence, and biology is constantly integrating with engineering sciences such as chemistry, artificial intelligence and materials science.

Angobo further stated that AI has the potential to be an accelerator for the development of next-generation medicines and therapeutic solutions. Merck scientists have also fully recognized the great potential of artificial intelligence in the fields of preclinical data analysis and biomarker determination in drug development, and have taken the application of artificial intelligence as an important part of the digital strategy to give full play to its role in drug research and development. Especially the advantages in compound optimization, molecular and compound testing, processing, etc. And, Merck has also applied advances in artificial intelligence to the screening of thousands of drug compounds. With artificial intelligence and learning and data processing capabilities, we help customers and partners we serve to save money in drug development and production process optimization. lot of time.

In addition, he also introduced that in the field of electronic technology business, Merck is actively committed to the innovation of existing computer architectures. With the help of innovative materials in the field of semiconductors, Merck has become an important promoter of the artificial intelligence revolution in the field of medicine and health. At the same time, it is also applying artificial intelligence technology in a very wide range of fields and continuously expanding the scope of applications, and has reached partnerships with many companies.

Finally, Angober also emphasized that Merck believes that artificial intelligence has the potential to reshape medicine broadly and improve the experience for clinicians, especially patients. “At Merck, we are confident in the power of artificial intelligence, and we believe it will help create a brilliant future.”

The following is the full text of the speech:

Hello everyone, I am An Gaobo, President of Merck China and Managing Director of Merck China Electronics Technology China. Thanks to the invitation of BEYOND International Technology Innovation Expo for allowing me to meet you in such a brand new metaverse space. It is an honor to share some views on artificial intelligence and biomedicine with you here, and introduce some gratifying achievements of Merck China in artificial intelligence-enabled medicine and health.

Merck is the world’s leading technology company, and artificial intelligence is used in Merck’s daily business operations and research and development. For Merck, artificial intelligence is our best choice, because Merck’s broad product line in the three major business areas of medicine and health, life sciences, and electronic technology complements the synergies brought by artificial intelligence. Merck’s persistent exploration of natural science has become more effective with the blessing of artificial intelligence, and biology is being merged with engineering sciences such as chemistry, artificial intelligence and materials science. With the integration of these sciences and disciplines, Merck is a reliable partner to the industry.

AI has the potential to be an accelerator for the development of next-generation medicines and therapeutic solutions. This enables more personalized and targeted treatment options, and will further improve treatment efficiency and accessibility for patients, which is highly anticipated. Merck scientists fully recognize the significant potential of artificial intelligence in areas such as preclinical data analysis for drug development, biomarker determination, and more. We take the application of artificial intelligence as an important part of our digital strategy, and give full play to its advantages in drug research and development, especially compound optimization, molecular and compound testing, and processing. Not only do we use artificial intelligence in the R&D process, Merck’s life sciences business also uses it in the R&D and production processes of our partners. We fully serve all aspects of biomedical research and development by providing innovative materials, equipment and technological solutions powered by artificial intelligence. Merck applies advances in artificial intelligence to the screening of thousands of drug compounds. With artificial intelligence and learning and data processing capabilities, we help customers and partners we serve save significant time in optimizing drug development and manufacturing processes .

As part of the rapidly growing Merck business matrix, in our Electronic Technology business area, Merck is actively working on the innovation of existing computer architectures. With the help of innovative materials in the semiconductor field, we have become an important promoter of the artificial intelligence revolution in the field of medicine and health. We provide key materials for neuromorphic chips and quantum computing. In China, we provide more than 150 key materials and products to more than 100 chip manufacturers, covering the entire process of wafer manufacturing and packaging. In the field of electronic technology, we will double our investment in China, that is, by 2025, we will invest another 1 billion yuan (about 13 million euros) to focus on the chip manufacturing industry. Globally, Merck will invest 3 billion euros in the same sector by 2025.

At Merck, we have been using artificial intelligence technology in a very wide range of fields for a long time and continue to expand the scope of application. Merck cooperates with French company Iktos to use artificial intelligence-based active ingredient research to accelerate drug development, and develop new treatments for some diseases through new technologies such as virtual new molecular autonomous design. In China, Merck has partnered with Insilico to accelerate the development of small molecules through the groundbreaking “Chemistry42” artificial intelligence platform. Through cooperation with leading industry companies, well-known scientific research institutions and universities, Merck has established an innovation platform called KEEN. A series of artificial intelligence applications have been developed under this platform. These include self-optimizing production cells. At the same time, Merck is investing in artificial intelligence in its own production process. Currently, a pilot project between Merck and Siemens is running.

As we all know, the scope of biomedicine is very broad and involves various medical research disciplines such as genetic epidemiology, clinical epidemiology, clinical virology and medical microbiology. The natural and engineering sciences are rapidly converging, allowing us to better understand human health and disease – such as anatomy, cell biology, biochemistry, microbiology, genetics, molecular biology, immunology, mathematics, statistics and bioinformatics, etc. All this interdisciplinarity requires huge datasets, which makes AI very helpful for the development of biomedical sciences and emerging therapeutic technologies. Case in point: Our scientists are actively experimenting with “organ-on-a-chip” solutions. While research is moving from “in vivo” to “in vitro,” sophisticated algorithms help process the vast amounts of data generated. While scientists and human know-how remain indispensable, AI has the fascinating ability to evaluate a large number of outcomes without direct human intervention. It can assist in text mining, patient-centric information retrieval, biomedical text evaluation, diagnostic assistance, clinical event prediction and many other tasks.

Merck believes that AI has the potential to reshape medicine broadly and improve the experience for clinicians, especially patients. Nonetheless, for all of us actively applying artificial intelligence, huge challenges remain.One of the biggest challenges is AI Create the necessary user trust in the system and how the training dataset is composed. That’s why Merck is also actively involved in developing appropriate management systems for the responsible and fair use of data, including ethnic monitoring. At Merck, we are confident in the power of artificial intelligence, and we believe it will help create a brilliant future.

Leave a Comment